Chemotherapy Tyrosine Kinase Inhibitors Epigenetics Wnt Signaling Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy DNA BCL Inhibitors Cyclin Dependent Kinase Inhibitors Serine-Threonine Kinase Inhibitors EGFR PARP Inhibitors | Breast Cancer | Hormone Receptor Positive Breast Cancer | Solid Tumor | Gastric Cancer | Hormone Receptor Negative Breast Cancer | Lung Adenocarcinoma | Triple Negative Breast Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Ovarian Cancer | Colorectal Cancer |
---|---|---|---|---|---|---|---|---|---|---|---|
fam-trastuzumab deruxtecan-nxki | |||||||||||
eribulin mesylate | |||||||||||
BB-1701 | |||||||||||
ado-trastuzumab emtansine | |||||||||||
disitamab vedotin | |||||||||||
trastuzumab duocarmazine | |||||||||||
BNT323 | |||||||||||
ribociclib | |||||||||||
palbociclib | |||||||||||
abemaciclib | |||||||||||
BL-M07D1 | |||||||||||
SHR-A1811 | |||||||||||
MRG002 | |||||||||||
KN046 + KN026 | |||||||||||
pyrotinib | |||||||||||
IKS014 | |||||||||||
albumin-bound paclitaxel + cyclophosphamide + epirubicin | |||||||||||
fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy | |||||||||||
trastuzumab-pkrb | |||||||||||
IMM2902 | |||||||||||
DAN-311 | |||||||||||
olaparib + niraparib + trastuzumab duocarmazine | |||||||||||
SAR446309 | |||||||||||
SAR443216 | |||||||||||
XMT-2056 | |||||||||||
disitamab vedotin + ABBV-IMAB-TJC4 | |||||||||||
trastuzumab + durvalumab |